🇺🇸 Cisplatin, paclitaxel in United States

36 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Second Primary Malignancy — 6 reports (16.67%)
  2. White Blood Cell Count Increased — 6 reports (16.67%)
  3. Acute Monocytic Leukaemia — 4 reports (11.11%)
  4. Malignant Neoplasm Progression — 4 reports (11.11%)
  5. Hypoglycaemia — 3 reports (8.33%)
  6. Ill-Defined Disorder — 3 reports (8.33%)
  7. Metastases To Lymph Nodes — 3 reports (8.33%)
  8. Pain — 3 reports (8.33%)
  9. Acute Myeloid Leukaemia — 2 reports (5.56%)
  10. Acute Myelomonocytic Leukaemia — 2 reports (5.56%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Cisplatin, paclitaxel approved in United States?

Cisplatin, paclitaxel does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Cisplatin, paclitaxel in United States?

Karolinska University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.